Shots:
- Eli Lilly has entered into a global licensing & multi-target research collaboration with Creyon Bio to identify, develop & market novel RNA-targeted oligonucleotide therapies for Lilly’s named targets using Creyon’s AI-powered Oligo Engineering Engine
- As per the deal, Lilly will get exclusive rights of lead candidates & handle further research, development & marketing upon achievement of certain milestones in exchange for $13M upfront in cash & equity, plus ~$1B in development & commercial milestones
- Oligo Engineering Engine accelerates development timelines by using principles of quantum chemistry, while reducing reliance on conventional trial-&-error methods to develop RNA-targeted oligo therapies
Ref: Businesswire | Image: Eli Lilly & Creyon Bio
Related News:- BigHat Biosciences Collaborates with Eli Lilly to Advance AI-Driven Antibody Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
